Peptidomics of cancer-derived enzyme products /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Hu, Xiaohua, 1960- (Editor ), Tamanoi, Fuyuhiko (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cambridge, MA : Academic Press, 2017.
Edición:First edition.
Colección:Enzymes ; v. 42.
Temas:
Peptides > Analysis.
Peptides > analysis
Peptides > Analyse.
SCIENCE > Life Sciences > Biology.
Peptides > Analysis
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 i 4500
001 SCIDIR_on1007309836
003 OCoLC
005 20231120010226.0
006 m o d
007 cr |n|||||||||
008 171025s2017 maua ob 000 0 eng d
040 |a YDX  |b eng  |e rda  |e pn  |c YDX  |d N$T  |d IDEBK  |d N$T  |d EBLCP  |d OPELS  |d UPM  |d OCLCF  |d OHS  |d OCLCO  |d MEU  |d D6H  |d AU@  |d YDX  |d INT  |d OCLCQ  |d OCLCA  |d OCLCQ  |d BRX  |d OCLCQ  |d S2H  |d OCLCQ  |d OCLCO  |d DKU  |d OCLCO  |d OCLCQ  |d OCLCO  |d OCLCQ  |d OCLCO 
066 |c (S 
019 |a 1007130083  |a 1028923634  |a 1029499755  |a 1030777752  |a 1032678883  |a 1034690310  |a 1038775124  |a 1039473152  |a 1084543079  |a 1264975396 
020 |a 9780128126394  |q (electronic book) 
020 |a 0128126396  |q (electronic book) 
020 |z 9780128126387 
020 |z 0128126388 
035 |a (OCoLC)1007309836  |z (OCoLC)1007130083  |z (OCoLC)1028923634  |z (OCoLC)1029499755  |z (OCoLC)1030777752  |z (OCoLC)1032678883  |z (OCoLC)1034690310  |z (OCoLC)1038775124  |z (OCoLC)1039473152  |z (OCoLC)1084543079  |z (OCoLC)1264975396 
050 4 |a QP552.P4  |b P478 2017 
055 1 3 |a QP601.  |b E522 1970 v.42eb 
072 7 |a SCI  |x 008000  |2 bisacsh 
082 0 4 |a 572/.65  |2 23 
082 0 4 |a 574.19/2456  |2 23 
245 0 0 |a Peptidomics of cancer-derived enzyme products /  |c edited by Tony Y. Hu, Fuyuhiko Tamanoi. 
250 |a First edition. 
264 1 |a Cambridge, MA :  |b Academic Press,  |c 2017. 
300 |a 1 online resource (xvi, 172 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a The enzymes ;  |v volume forty two 
546 |a Text in English. 
504 |a Includes bibliographical references. 
505 0 |6 880-01  |a Front Cover -- Peptidomics of Cancer-Derived Enzyme Products -- Copyright -- Contents -- Contributors -- Preface -- Overview -- 1. Molecular Changes in Cancer -- 2. Peptidomes and Advance in Mass Spectrometry -- 3. Nanotechnology and Nanodevices -- 4. Future Perspective -- Chapter One: Circulating Peptidome and Tumor-Resident Proteolysis -- 1. Introduction -- 1.1. Intracellular Proteases -- 1.1.1. Caspases (Cysteine Protease) -- 1.1.2. Deubiquitinases (Cysteine and Zinc Proteases) -- 1.1.3. Autophagins (Cysteine Proteases) -- 1.2. Extracellular Proteases 
505 8 |a 1.2.1. Matrix Metalloproteinases1.2.2. Cysteine Cathepsins -- 1.2.3. Kallikreins -- 2. Organism and Cancer Degradomes -- 3. Tumor-Associated Peptidomics -- 4. Tumor Proteases Relative Peptide in Cancer Detection -- 5. Conclusion -- References -- Chapter Two: The Peptidome Comes of Age: Mass Spectrometry-Based Characterization of the Circulating Cancer Peptidome -- 1. Introduction -- 2. Biological Role of Peptides -- 3. Peptidomics: The Study of Physiological Peptides -- 4. Mass Spectrometry and Top/Middle-Down Proteomics 
505 8 |a 4.1. Mass Spectrometry Technology Developments for Peptidomics4.2. Top-Top-Down or Native Mass Spectrometry -- 4.3. Top-Down-Based Mass Spectrometric Imaging -- 5. Strategies to Enrich the Peptidome -- 5.1. Selective Precipitation -- 5.2. Centrifugal Ultrafiltration -- 5.3. Capillary Ultrafiltration -- 5.4. Surface-Derivatised Magnetic Beads -- 5.5. Nanoporous Substrates -- 6. Application of Peptidomics in Cancer Biomarker Discovery -- 6.1. Role of Peptidomics as in Cancer Biomarker Discovery -- 6.2. Peptidomics and Cancer Diagnosis 
505 8 |a 6.3. Plasma Protein/Peptide Profiling6.4. The Plasma Interactome -- 6.5. Endoproteolytic Cleavage -- 6.6. Exoproteolytic Cleavage -- 7. Data Processing and Informatics for Peptidome Analyses -- 7.1. Sequence Databases -- 7.2. Data Analyses -- 7.3. Data Repository -- 8. Emerging Technologies -- 9. Future Perspectives -- Acknowledgments -- References -- Chapter Three: Peptide Hormones as Tumor Markers in Clinical Practice -- 1. Introduction -- 2. Selected Peptide Hormones as Tumor Markers -- 2.1. Calcitonin -- 2.1.1. Biosynthesis From Prohormone 
505 8 |a 2.1.2. Clinical Significance as Tumor Marker2.2. Alpha- and Beta-hCG -- 2.2.1. Processing of hCG -- 2.2.2. Clinical Applications as Tumor Markers -- 2.3. Insulin and C-Peptide -- 2.3.1. Biosynthesis From Prohormone -- 2.3.2. Clinical Significance as Tumor Marker -- 2.4. PTHrp -- 2.4.1. Biosynthesis From Prohormone -- 2.4.2. Clinical Significance as Tumor Marker -- 2.5. Gastrin -- 2.5.1. Biosynthesis From Prohormone -- 2.5.2. Clinical Significance as Tumor Marker -- 2.6. VIP -- 2.6.1. Biosynthesis From Prohormone 
588 0 |a Online resource; title from digital title page (viewed on June 11, 2018). 
650 0 |a Peptides  |x Analysis. 
650 2 |a Peptides  |x analysis  |0 (DNLM)D010455Q000032 
650 6 |a Peptides  |0 (CaQQLa)201-0006528  |x Analyse.  |0 (CaQQLa)201-0374819 
650 7 |a SCIENCE  |x Life Sciences  |x Biology.  |2 bisacsh 
650 7 |a Peptides  |x Analysis  |2 fast  |0 (OCoLC)fst01057565 
700 1 |a Hu, Xiaohua,  |d 1960-  |e editor. 
700 1 |a Tamanoi, Fuyuhiko,  |e editor. 
773 0 |t Enzymes. 
773 0 |t Elsevier. 
776 0 8 |i Print version:  |t Peptidomics of cancer-derived enzyme products.  |b First edition.  |d Cambridge, MA : Academic Press, 2017  |z 9780128126387  |z 0128126388  |w (OCoLC)985078856 
830 0 |a Enzymes ;  |v v. 42. 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/bookseries/18746047/42  |z Texto completo 
880 0 0 |6 505-01/(S  |g Machine generated contents note:  |g 1.  |t Circulating Peptidome and Tumor-Resident Proteolysis /  |r Tony Y. Hu --  |g 1.  |t Introduction --  |g 2.  |t Organism and Cancer Degradomes --  |g 3.  |t Tumor-Associated Peptidomics --  |g 4.  |t Tumor Proteases Relative Peptide in Cancer Detection --  |g 5.  |t Conclusion --  |t References --  |g 2.  |t Peptidome Comes of Age: Mass Spectrometry-Based Characterization of the Circulating Cancer Peptidome /  |r Richard J. Simpson --  |g 1.  |t Introduction --  |g 2.  |t Biological Role of Peptides --  |g 3.  |t Peptidomics: The Study of Physiological Peptides --  |g 4.  |t Mass Spectrometry and Top/Middle-Down Proteomics --  |g 5.  |t Strategies to Enrich the Peptidome --  |g 6.  |t Application of Peptidomics in Cancer Biomarker Discovery --  |g 7.  |t Data Processing and Informatics for Peptidome Analyses --  |g 8.  |t Emerging Technologies --  |g 9.  |t Future Perspectives --  |t Acknowledgments --  |t References --  |g 3.  |t Peptide Hormones as Tumor Markers in Clinical Practice /  |r Zhen Zhao --  |g 1.  |t Introduction --  |g 2.  |t Selected Peptide Hormones as Tumor Markers --  |g 3.  |t Conclusion --  |t Acknowledgement --  |t References --  |g 4.  |t Insights on the HLA-Binding Peptidome in Cancer /  |r Douglas F. Lake --  |g 1.  |t Introduction --  |g 2.  |t Proteolysis of Proteins to Peptide Loading onto MHC --  |g 3.  |t Dysregulation of Antigen Processing in Cancer --  |g 4.  |t Tumor-Derived Defective Ribosomal Products --  |g 5.  |t Noncoding RNA Peptides --  |g 6.  |t Outlook --  |t References --  |g 5.  |t Strategies for Characterization of Low-Abundant Intact or Truncated Low-Molecular-Weight Proteins From Human Plasma /  |r Fuquan Yang --  |g 1.  |t Introduction --  |g 2.  |t Strategies for the Prefractionation or Enrichment of Small Intact or Truncated Proteins From the Human Plasma --  |g 3.  |t Characterization of LMW Proteins Based on MS --  |g 4.  |t Future Perspectives and Concluding Remarks --  |t Acknowledgments --  |t References --  |g 6.  |t Saliva-Exosomics in Cancer: Molecular Characterization of Cancer-Derived Exosomes in Saliva /  |r David T.W. Wong --  |g 1.  |t Introduction --  |g 2.  |t Salivaomics in Cancer --  |g 3.  |t Saliva-Exosomics: Next-Generation Salivaomics --  |g 4.  |t Salivary Exosomes as Potential Biomarkers for Cancer --  |g 5.  |t Future Perspective --  |t Acknowledgments --  |t Disclosure Statement --  |t References --  |g 7.  |t Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy /  |r Fuyuhiko Tamanoi --  |g 1.  |t Introduction --  |g 2.  |t Overview of Enzymes Used --  |g 3.  |t Protease Activatable Systems --  |g 4.  |t Hyaluronidase Activatable System --  |g 5.  |t Protein Kinase Cα Activatable System --  |g 6.  |t Esterase Activatable System --  |g 7.  |t Enzyme-Activated Nanovalves and Controlled Release of Anticancer Drugs --  |g 8.  |t Multistage Delivery Strategy --  |g 9.  |t Azoreductase and Colon-Specific Delivery --  |g 10.  |t Future Perspectives. 

Ejemplares similares